- Home
- FMAO vs XOMA Comparison
FMAO vs XOMA Comparison
Compare FMAO & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- XOMA
- Stock Information
- Founded
- FMAO 1897
- XOMA 1981
- Country
- FMAO United States
- XOMA United States
- Employees
- FMAO N/A
- XOMA N/A
- Industry
- FMAO Savings Institutions
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- FMAO Finance
- XOMA Health Care
- Exchange
- FMAO Nasdaq
- XOMA Nasdaq
- Market Cap
- FMAO 356.9M
- XOMA 330.2M
- IPO Year
- FMAO N/A
- XOMA N/A
- Fundamental
- Price
- FMAO $26.13
- XOMA $32.47
- Analyst Decision
- FMAO
- XOMA Strong Buy
- Analyst Count
- FMAO 0
- XOMA 2
- Target Price
- FMAO N/A
- XOMA $69.50
- AVG Volume (30 Days)
- FMAO 21.8K
- XOMA 57.0K
- Earning Date
- FMAO 10-29-2025
- XOMA 08-13-2025
- Dividend Yield
- FMAO 3.34%
- XOMA N/A
- EPS Growth
- FMAO 38.39
- XOMA N/A
- EPS
- FMAO 2.16
- XOMA N/A
- Revenue
- FMAO $108,632,000.00
- XOMA $44,952,000.00
- Revenue This Year
- FMAO $1.60
- XOMA $82.30
- Revenue Next Year
- FMAO $13.77
- XOMA $12.59
- P/E Ratio
- FMAO $12.26
- XOMA N/A
- Revenue Growth
- FMAO 13.86
- XOMA 194.98
- 52 Week Low
- FMAO $20.88
- XOMA $18.35
- 52 Week High
- FMAO $34.15
- XOMA $35.23
- Technical
- Relative Strength Index (RSI)
- FMAO 58.09
- XOMA 61.79
- Support Level
- FMAO $24.60
- XOMA $32.60
- Resistance Level
- FMAO $27.01
- XOMA $34.60
- Average True Range (ATR)
- FMAO 0.81
- XOMA 1.82
- MACD
- FMAO 0.23
- XOMA 0.09
- Stochastic Oscillator
- FMAO 89.44
- XOMA 66.75
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company based in Ohio. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.